Improved losses driven by cost discipline and non-operating gains from ONCO equity realizations, though heavy cash burn persists amid clinical investments and going concern warnings.
Key takeaways
Diluted EPS worsened to -$0.12 from -$0.05 due to higher share count post equity raise diluting per-share results.
Operating cash burn eased to -$15.1M from working capital timing and lower expenses, but still heavy.